<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20007">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912911</url>
  </required_header>
  <id_info>
    <org_study_id>13-521</org_study_id>
    <nct_id>NCT01912911</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy and Feasibility of a Novel Wireless ECG Recording System in Monitoring Patients After Atrial Fibrillation Ablation Procedure</brief_title>
  <acronym>iTransmit</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators goal in this study is to examine the feasibility and efficacy of AliveCor
      iphone case monitoring device in monitoring patients after AF ablation by comparing
      transmissions using Alive Cor with transmissions from a traditional transtelephonic monitor
      (TTM).

      A secondary goal is to assess the ease of use of AliveCor device compared to traditional TTM
      system from the patient's perspective
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The proportion of AF/flutter events detected by the AliveCor device will be compared to events detected by the TTM for each episode.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of transmissions from smartphone in comparison with traditional TTM method</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing A-fib ablations.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female between &gt; 18 and &lt; 75 years of age

          2. Paroxysmal or persistent atrial fibrillation

          3. Scheduled to undergo an AF ablation procedure

          4. Already has iPhone 4 or iPhone 4S with data plan

          5. Willing to use the iPhone Alive Cor case

          6. Written informed consent

        Exclusion Criteria:

          1. Unable or unwilling to use the Alive Cor case for their iPhone or iPhone 4S

          2. Residing outside the United States
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khaldoun Tarajki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic HVI</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Khaldoun Tarakji, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>June 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Khaldoun Tarakji</investigator_full_name>
    <investigator_title>MD MPH</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
